J&J reveals plans to appeal cancer drug court ruling

29-10-2018

J&J reveals plans to appeal cancer drug court ruling

Bill Oxford / IStockphoto.com

Johnson & Johnson (J&J) has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).


J&J, Johnson & Johnson, Zytiga, cancer drug, generics, ANDA, prostate cancer, patent invalidation

LSIPR